Metastatic Castrate-Resistant Prostate Cancer Treatment (mCRPC)

 

The aim of this evaluation form is to gain your feedback, in order to maintain high educational standards and provide a reference for continuous improvement. Please indicate which rating reflects your answer.

Questions marked with are required.

1. Did this E-Learning module provide an overview of available first-line treatments that represent standard of care in patients with metastatic castrate-resistant prostate cancer (mCRPC)? (1-not at all; 5-yes absolutely)

2. Did this E-Learning module provide an overview of new hormonal drugs under development, immunotherapy approaches and targeted agents of relevance for patients with mCRPC? (1-not at all; 5-yes absolutely)

3. Did this E-Learning module critically analyze lessons learned from failed clinical trials in patients with mCRPC ? (1-not at all; 5-yes absolutely)

4. Please, provide your overall rating of the quality of the education offered by this E-Learning module. (1-poor; 5-excellent)

5. How would you rate the interactivity level offered in the E-Learning material? (1-poor; 5-excellent)

6. Was the information useful and relevant to your work and practice? (1-not at all; 5-absolutely)

7. Do you feel that the information presented was well balanced and supported by adequate evidence? (1-not at all; 5-absolutely)

8. Do you think that the scientific content of this E-learning activity contains any commercial material?

9. If you answered YES, please motivate your choice in the box below:

10. If you would like to add your personal comments or make suggestion to improve future ESMO E-Learning material, please write in the box below: